# The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

> **NCT00345059** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute, Naples** · enrollment: 84 (actual)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** vinorelbine
- **DRUG:** gemcitabine
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00345059
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2016-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345059, "The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00345059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*